<DOC>
	<DOCNO>NCT00300430</DOCNO>
	<brief_summary>The primary purpose study test safety effect use investigational drug regimen ; daily ABT-335 ( Investigational drug ) administer combination daily atorvastatin calcium , rosuvastatin calcium simvastatin patient abnormal lipid level blood .</brief_summary>
	<brief_title>Study Evaluate Long-Term Safety Efficacy ABT-335 , Combination With Three Different Statins Subjects With Mixed Dyslipidemia .</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Adult male female subject voluntarily sign informed consent . Subject successfully complete one three ABT335 , rosuvastatin , simvastatin atorvastatin combination therapy study . Subject use use investigational medication , except approve Abbott . Subject prematurely discontinue his/her initial therapy one prior ABT335 , rosuvastatin , simvastatin atorvastatin calcium combination therapy study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>